F.H. Investments, Inc., Birmingham, AL
Is F.H. Investments, Inc. registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names F.H. Investments, Inc. in Birmingham, AL, first registered May 13, 2025 and most recently registered Dec 2, 2025.
Does F.H. Investments, Inc. hold a Alabama pharmacy license?
State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018121 for FH INVESTMENTS INC, BIRMINGHAM, AL, status CLOSED and license 054019889 for FH INVESTMENTS INC, BIRMINGHAM, AL, status NOT RENEWED, as of Nov 13, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301013793 for F.H. INVESTMENTS, INC., Birmingham, AL, status Active, as of Nov 10, 2026.
Has F.H. Investments, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 2 FMD-145 letters (Sep 10, 2021 and May 8, 2025) for F.H. Investments, Inc. State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- F.H. Investments, Inc.; FH Investments Inc.; Asteria Health
- Location
- Birmingham, AL
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as F.H. Investments, Inc.
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Dec 19, 2025
- FDA Data Dashboard inspections
- 2 inspections: 2 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 15 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as FH Investments Inc., (dba Asteria Health), a 503B facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Dec 19, 2025 | Form 483 | 483 Issued 12/19/2025 | fda.gov |
| May 8, 2025 | FMD-145 letter | FMD-145 Letter Issued 05/08/2025 | Not linked by FDA |
| Nov 8, 2024 | Form 483 | 483 Issued 11/08/2024 | FDA copy (archived) |
| Sep 10, 2021 | FMD-145 letter | FMD-145 Letter Issued 09/10/2021 | Not linked by FDA |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists F.H. Investments Inc., Birmingham, AL (FEI number 3010348724), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 8, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010348724 | 1255751 |
| Jul 10, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010348724 | 1063438 |
Form 483s FDA has published for this site
- Nov 8, 2024: Form 483 to F.H. Investments Inc., published Feb 7, 2025. fda.gov
- Oct 24, 2018: Form 483 to F.H. Investments Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 15 numbered observations in all, across 2 inspections ending Nov 8, 2024 to Dec 19, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Dec 5, 2025 to Dec 19, 2025: 10 observations
- Firm on the cover
- F.H. Investments, Inc. (dba Asteria Health), 432 Industrial Ln, Birmingham, AL 35211-4465
- FEI number
- 3038253438
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, 503B list
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
Your firm has been manufacturing and distributing implantable hormone pellets since May 2025 without conducting process validation. Your firm has not performed Performance Qualification (PQ) on any equipment used for drug production nor has your firm executed Process Validation Qualification (PPQ) for any of your drug products. Your justification includes legacy data from commercial batches produced and distributed and claims of no changes to equipment, formulation, and materials.
However, your fnm has made changes to your manufacturing process by, for example:
• Adding new equipment (i.e., metal detectors, weight sorters) that were not previously apart of your manufacturing process
• Changing drug formulation in the master batch record. For example, changing the ratio of active pharmaceutical ingredient and excipient for Testosterone/Anastrozole pellet products.
• Changing the visual inspection and sampling process ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically,
Your non-representative dose audits does not provide assurance that commercial hormone pellet products achieve sterility or maintain quality after sterilization., for the following hormone pellets that were manufactured and released at this facility.
Pellets Produced / Batch*
Number of Released Batches
Drug Product
Strengths
Length
BUD*
12.5mg, 18mg, 25mg, 37.5mg, 50mg, 62.5mg, 87.5mg, 100mg, 200mg,303mg
<Redacted B4>
3.2mm <Redacted B4>
Testosterone
365 days
6mg, 10mg, 12.5mg, 15mg, 18mg, 20mg, 22mg, 25mg, 37.5mg
3.2mm
<Redacted B4> <Redacted B4> I
Estradiol
3.2mm/ 4.3mm
<Redacted B4>
<Redacted B4> ]
, Testosterone/ Anastrozole
60mg/4mg, 75mg/4mg100mg/4mg, 200mg/10mg
3.2mm/ 4.5mm <Redact ed B4> <Redacted B4> I
*Data derived from 001.2 Drug production log for May 2025 to December 2025.
**Expiration date is either 365 days <Redacted B4> or the <Redacted B4>
I
Your firm relies on sterility data from a non-representative batch (e.g. ...
Observation 3
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
A. Your quality unit has failed to ensure appropriate oversight for changes to master batch records. For example, as part of PRO25-035, your firm updated the powder formulation for Testosterone Anastrozole products. However, your quality unit failed to appropriately review and adjust the weight of <Redacted B4> accordingly, leading to inconect formulation direction or pellet weighing specifications issued for manufacturing the following, including but not limited to:
weighing specifications issued for manufacturing the following, including but not limited to:
• Testosterone/Anastrozole 200mg/10mg, Lot <Redacted B4> REJECTED due to "pellets would not hold together." Your investigation1 DV25-042) determined that it was an error in the master batch record leading to formulation failure.
• Testosterone/Anastrozole 60mg/4mg, Lot <Redacted B4> REJECTED due to failed in process potency testing. Your investigation (DV25-046) determined that it was an error in the master batch record leading to potency failure. ...
Observation 4
The quality control unit lacks authority to review production records to assure that no errors have occurred and folly investigate en ors that have occurred.
Specifically,
A. Your quality unit failed to investigate the following events:
• Rejected Estradiol 6mg, Lot <Redacted B4> on July 10, 2025, for "issues experienced with powder during pressing" without opening any investigation.
• No investigation was conducted for a confirmed laboratory out-of-specification investigation (OOS25-004, failed potency testing due to broken pellet).
B. Inadequate investigation of recurring metallic and foreign contamination events:
Root Cause(s) as determined by the firm
Date
Deviation /CAPA
Contamination Event
DV25-035/ CAPA25-016
Metallic shavin, from microcapper <Redacted B4> pellets rejected
Inadequate maintenanc e procedure
DV25-041/ CAPA25-024
Metal shavings from pellet presses <Redacted B4> and or <Redacted B4> batches rejected
Insufficient operator training, component wear
06/27/2025, 07/01/2025
DV25-070/ CAPA25-041
Metallic shavings from microcappers <Redacted B4> and <Redacted B4>, batch rejected Internal wear ocomponents ...
Observation 5
Aseptic processing areas are deficient in that wall are not smooth and/or hard surfaces that are easily cleanable.
Specifically,
For example:
4 • Testosterone 200mg, Lot 251000180, EXP 09/1 9/2026 (QTY <Redacted B4> RELEASED
4 • Estradiol l0mg, Lot 253000132, EXP 06/1 6/2026 (QTY <Redacted B4> ) -RELEASED
• Estradiol 12.5mg, Lot 253000130, EXP 06/16/2026 (QTY <Redacted B4>) -RELEASED
Observation 6
Each batch of controlled-release dosage form drug product is not laboratory tested to determine conformance to the specifications for the rate of release for each active ingredient.
Specifically,
Your firm's current release testing program involving weight, pellet length, endotoxin, dosimetry and potency testing is inadequate to ensure the quality of solid dosage forms intended for <Redacted B4>. Your firm has failed to establish appropriate release testing specifications for implantable hormone pellets, including:
• Absence of dissolution testing for batch release to ensure consistent drug release and prevent dose dumping, control batch variability, and quality control for implantable products.
• Absence of hardness/friability testing for batch release to ensure pellets maintain structural integrity during the intended multi-month implantation period.
1,(a.;;:) Your firm has released more than <Redacted B4> batches covering over <Redacted B4> pellets to patients across "states I since May 2025 without adequate release testing, failing to ensure that hormone pellets meet appropriate standards of identity, strength, quality, and purity before distribution to patients.
Observation 7
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Specifically,
Your firm did not initiate stability studies until December 3, 2025, for implantable pellet products manufactured at this facility. Stability studies should have been conducted before releasing products to the market to support beyond use dating/expiration dating on your product labels. In the absence of stability data generated from batches manufactured at this facility, you assigned an expiry of 365 days for all batches based on legacy data from another facility. Your justification that you have the same equipment, formulation, materials are inappropriate as:
• Environmental conditions including microbial floras may differ
• Material and people flow during manufacturing may differ
• Facility layout, construction, and HV AC systems may differ
• Manufacturing process validation may differ
Legacy data from different facilities cannot substitute for facility-specific stability data required to support expiration dating and batch release.
Observation 8
Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
Specifically,
Your laboratory manager reviews only printed chromatograms and audit trail data without reviewing raw electronic data. This process does not ensure the accuracy and reliability of analytical results used for batch release decisions. The lack of review of raw electronic data generated by analytical instruments limits the ability to detect data integrity issues and system malfunctions that could affect batch release decisions.
Observation 9
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically,
A. Unrestricted analytical system access where your lab manager logged into the <Redacted B4> chromatography system on December 4, 2025, without user login credentials and operated under "Admin" user profile with unrestricted access to audit trails, methods, and sequences deletions. Sequence reports since May 2025 show all potency testing for batch release was performed under "admin" accounts, compromising data integrity for critical quality decisions.
I
B. Inadequate batch record and document control where environmental monitoring, personnel monitoring, sampling, and visual inspection forms that support batch release decisions are accessible for unlimited printing by non-QC personnel without reconciliation controls such as date/time stamps, page number, issuance tracking.
accessible for unlimited printing by non-QC personnel without reconciliation controls such as date/time stamps, page number, issuance tracking.
C. ...
Observation 10
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing, and processing.
e
Specifically,
Your firm implemented metal detection testing approximately in October 2025 for each pellet batch as a corrective measure to identify metal shavings and particles that had been found in previous batches beginning in June 2025. However, the results of these metal detection tests are not documented. Additionally, when metal contamination is identified, the contaminated pellets and metal fragments ai·e discarded as waste. The lack of metal detection documentation in batch records may impair the quality unit's capacity to make well-informed batch release determinations.
Inspection Oct 28, 2024 to Nov 8, 2024: 5 observations
- Firm on the cover
- F.H. I nvestments Inc., 7004 Champion Blvd Ste 100, Bimingham, AL 35242-6500
- FEI number
- 3010348724
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
You failed to conduct complaint investigations for the following customer reported product quality issues regarding your sterile compounded drug pellets:
• Complaint, CC024-002, dated 09/13/24; Pellets did not fit into trocar kits used for subdermal placement: Testosterone 37.5 mg, Lot <Redacted B4>; Testosterone 25 mg, Lot <Redacted B4> ; Testosterone 87.5 mg, Lot <Redacted B4>
• Complaint, CC024-04, dated 09/13/24; Multiple units received as only powder, no pellet:Estradiol 6 mg and 10 mg (no lot information)
• Complaint, CC024-07, dated 10/03/24; Pellet stuck in vial container: Estradiol 6 mg, Lot <Redacted B4>
• Complaint, CC024-09, dated 10/03/24; Pellet stuck in vial container and crumbled in tweezers: Estradiol 12.5 mg, Lot <Redacted B4>
• Complaint CC24-012, dated 10/21/24; Variable pellet color and shape; Testosterone 200 mg, Lot <Redacted B4>
• Complaint CC24-013, dated 10/21/224; Pellets did not fit into trocar kits used for subdermal placement: Testosterone 200 mg (not lot provided) ...
Observation 2
Each batch of controlled-release dosage form drug product is not laboratory tested to determine conformance to the specifications for the rate of release for each active ingredient.
Specifically,
Your firm failed to conduct dissolution testing as part of your finished product specification requirements prior to batch release, and therefore is unable to ensure subdermal implant pellets do not dissolve immediately, remain integral (do not crumble or break into pieces), and release active pharmaceutical ingredients at a rate that is reproducible. Dissolution testing has not been performed for the following sterile compounded drug products produced at your facility:
<Redacted B4> Estradiol 12.5 mg <Redacted B4> Estradiol 15 mg <Redacted B4> Estradiol 18 mg <Redacted B4> Estradiol 20 mg <Redacted B4> Estradiol 22 mg <Redacted B4> Estradiol 25 mg <Redacted B4> Estradiol 37.5 mg <Redacted B4> Testosterone 12.5 mg <Redacted B4> Testosterone 18 mg <Redacted B4> Testosterone 25 mg <Redacted B4> Testosterone 37.5 mg <Redacted B4> Testosterone 50 mg <Redacted B4> Testosterone 62.5 mg <Redacted B4> Testosterone 87.5 mg <Redacted B4> Testosterone 100 mg <Redacted B4> Testosterone 200 mg ...
Observation 3
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity ofthe drug product.
Specifically,
Your equipment cleaning process has not been validated to ensure there is no cross-contamination between hazardous and highly-potent hormone active pharmaceutical ingredients (APis), including, testosterone and estradiol. Your firm produces multiple compounded hormone drug products using non-dedicated equipment, including pellet presses that have multiple product contact parts, <Redacted B4> control hoods, analytical balances, and calipers. Additionally, a non-dedicated vacuum cleaner is used to remove powder drug substance from production equipment and surfaces. For example,
A) On October 29, 2024, your operator performed inadequate cleaning of product contact equipment and adjacent areas following production of Testosterone 100 mg pellets, Lot <Redacted B4> Exp 08/2025. A white residue was observed on the surfaces of the pellet press and the <Redacted B4> containment hood after post-production cleaning. ...
Observation 4
Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
Specifically,
Your firm lacks adequate controls to prevent cross-contamination within ISO 8 Anterooms. Anterooms are used for personnel gowning and storage of gowning materials, personal protection equipment (PPE), and cleaning equipment. Operators enter the anteroom in outside clothes and open new gowning within the same space that is exposed to hazardous powder drug product from gowning worn during production. For example:
are used for personnel gowning and storage of gowning materials, personal protection equipment (PPE), and cleaning equipment. Operators enter the anteroom in outside clothes and open new gowning within the same space that is exposed to hazardous powder drug product from gowning worn during production. For example: ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
Your firm relies on <Redacted B4> reported Certificates of <Redacted B4> as <Redacted B4> for batch release of your compounded hormone drug products purported to be sterile. Your firm lacks <Redacted B4> sterility testing results in 2024 to validate sterility assurance <Redacted B4> reported on certificates of <Redacted B4>
Linked 483s whose text is not shown
- Oct 24, 2018: FDA document 115061: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054018121 | LICENSED PHARMACY | FH INVESTMENTS INC | BIRMINGHAM, AL | CLOSED |
| 054019889 | LICENSED PHARMACY | FH INVESTMENTS INC | BIRMINGHAM, AL | NOT RENEWED |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301013793 | Pharmacy | F.H. INVESTMENTS, INC. | Birmingham, AL | Active |
FDA’s 503B list
- F.H. Investments, Inc., Birmingham, AL: last inspection Dec 19, 2025, Form 483 at that inspection: Yes, action FDA lists: Open.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Illinois Department of Financial and Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.